2024-03-21 07:00:00 ET
Summary
- My investment strategy is to fill my portfolio with remarkably reliable dividend growers.
- Abbott Laboratories posted fourth quarter net sales and non-GAAP EPS results ahead of and in line with the analyst consensus, respectively.
- The healthcare titan enjoys an AA- credit rating from S&P on a stable outlook.
- Abbott Laboratories' shares look to be priced 2% under fair value.
- The Dividend King could be positioned to match the total returns of the S&P 500 in the coming decade.
Since I began investing in September 2017, my investing strategy has predominantly been dividend growth-focused. To be clear, there are plenty of non-dividend stocks that have been excellent investments. I even own some of the premier non-dividend stocks like Amazon ( AMZN ) and Alphabet ( GOOG )( GOOGL ). There are also others that I am considering.
But I have found that the dividend growth investing strategy more easily filters for quality. Why is this my argument?...
Read the full article on Seeking Alpha
For further details see:
Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now